Valye reports for unlimited access

Dillard's, Inc. operates as a fashion apparel, cosmetics, and home furnishings retailer primarily in the southwestern, southeastern, and midwestern United States. The company runs 271 stores, including clearance centers, and an online store offering a broad merchandise selection. It also operates a construction segment through CDI Contractors, LLC, which handles store construction and remodeling. The company emphasizes exclusive private label brands to differentiate its merchandise and maintain competitive pricing. Dillard's sources products from multiple suppliers without long-term purchase commitments but maintains strong supplier relationships. The company’s fiscal year ends near January 31, with significant sales concentration in the holiday quarter. Dillard's also manages a private label credit card program through a long-term alliance with Citibank, which provides ongoing cash compensation based on portfolio earnings. The company employs over 29,000 associates and maintains a comprehensive information security program. Its operations face risks from supply chain disruptions, supplier compliance, and market competition.

Northpointe Bancshares, Inc. operates as a bank holding company with a focus on mortgage finance and retail banking services. Its primary business segments are the Mortgage Purchase Program (MPP), which provides collateralized mortgage purchase facilities to independent mortgage bankers nationwide, and Retail Banking, which includes residential lending, digital deposit banking, and loan servicing. The company leverages a proprietary digital platform to deliver services nationwide, supported by loan production offices in multiple states and a centralized operating center in Michigan. Northpointe is the largest bank headquartered in Michigan and a significant provider of mortgage warehouse financing. The company has strategically repositioned its business since 2022 to exit lower-margin correspondent lending, expand private-label subservicing, and increase specialized residential loan holdings, resulting in improved profitability and cost efficiency. It manages a range of risks through board oversight and maintains strong capital and liquidity positions. The company completed its IPO in February 2025 and is listed on the NYSE under ticker NPB.

GSR IV Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in May 2023 in the Cayman Islands. Its sole purpose is to identify and complete an initial business combination with one or more target companies. The company completed its IPO in September 2025, raising gross proceeds of $230 million, which are held in a Trust Account invested primarily in money market funds with U.S. government securities. As of the end of 2025, the company had not commenced operations and has no operating revenues. It generates non-operating income from interest and dividends earned on the Trust Account. The company has a high current ratio, reflecting strong liquidity. Its business strategy is to leverage the management team's experience in SPAC mergers and capital markets to target high-growth companies in sectors such as software, technology-enabled manufacturing and services, mobility, transportation, and companies addressing environmental, social, and governance (ESG) issues. The company has established acquisition criteria focusing on financial stability, market leadership, barriers to entry, growth potential, strong management, and ESG focus. The initial business combination must meet Nasdaq listing rules, including a fair market value test of at least 80% of the Trust Account assets. If the company does not complete a business combination within the prescribed timeframe, it may seek shareholder approval to extend or otherwise liquidate and return funds to shareholders. The company incurs administrative expenses, including fees paid to the Sponsor for office and support services, which cease upon completion of a business combination or liquidation.

Lifeloc Technologies, Inc specializes in breath alcohol testing devices utilizing fuel cell technology, which it has developed and refined over many years. The company operates globally, relying on third-party suppliers and service providers, and faces risks from natural disasters, geopolitical instability, and economic fluctuations. It serves customers including law enforcement and workplace safety sectors, with a notable concentration of sales to a few customers lacking long-term contracts. The company is engaged in a merger agreement to acquire Electronic Systems Technology, Inc. and has recently secured financing to support growth initiatives. Lifeloc maintains a strong liquidity position but reported a net loss for the fiscal year ending 2025. Its common stock is traded on OTC markets and is controlled predominantly by a principal stockholder.

Avidia Bancorp, Inc. is the holding company for Avidia Bank, headquartered in Hudson, Massachusetts, serving the western suburbs of Boston and eastern Worcester County. The bank operates 10 offices and offers a range of deposit accounts, including certificates of deposit, IRAs, money market accounts, savings, and checking accounts, as well as Health Savings Accounts nationwide through its Avidia Health program. The company’s lending activities focus on one-to-four-family residential mortgages, commercial real estate loans, commercial and industrial loans (notably condominium association and dental practice loans), and to a lesser extent, home equity, multifamily, construction, land, and consumer loans. The loan portfolio is managed with attention to interest rate risk, with a mix of fixed and adjustable-rate loans. The company also provides payments processing services as a sponsor bank, partnering with ISOs and fintechs to offer card issuing, card acquiring, and ACH payment solutions, generating substantial payment volumes and low-cost deposits. The company faces significant competition from a variety of financial institutions and fintech providers in its market area. The company completed its stock conversion in 2025, enabling capital growth and shareholder initiatives including dividends and an ESOP.

AIM ImmunoTech Inc. is an immuno-pharmaceutical company headquartered in Florida, specializing in the development of Ampligen, a double-stranded RNA molecule targeting cancers, viral diseases, and immune disorders. Ampligen is approved for commercial sale in Argentina for Chronic Fatigue Syndrome but remains unapproved by the FDA in the United States. The company is focusing its development efforts on late-stage pancreatic cancer, conducting clinical trials including the DURIPANC Phase 2 study evaluating Ampligen in combination with AstraZeneca's immune checkpoint inhibitor durvalumab. AIM also markets Alferon N Injection (Interferon alfa). The company generates revenue primarily from clinical treatment programs under cost recovery protocols. AIM faces challenges including limited supplier agreements for manufacturing materials and maintaining compliance with NYSE American listing requirements due to negative stockholders' equity. The company has raised capital through rights offerings and ATM sales agreements to support ongoing operations and clinical development.

Space Asset Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands on September 12, 2025. It was formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar Business Combination with one or more businesses. The company is not limited to any particular industry or geographic region but intends to focus on companies in the global space economy, including technology and defense sectors. The company completed its Initial Public Offering on January 29, 2026, issuing 23 million Units and raising gross proceeds of $230 million. Each Unit consists of one Class A ordinary share and one-third of one redeemable warrant. As of December 31, 2025, the company had no operating revenues and had incurred a net loss of $64,829 related to formation and administrative expenses. The company had current liabilities of $450,560 and no cash or cash equivalents reported at that date. The company has a Completion Period until January 29, 2028, to consummate its initial Business Combination, after which mandatory liquidation and dissolution will occur if no combination is completed. The company’s initial shareholders own approximately 26% of the issued and outstanding ordinary shares and may exert substantial influence on shareholder votes. The company may amend its charter or governing instruments to facilitate completion of a Business Combination, subject to shareholder approval thresholds under Cayman Islands law.

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing cell therapies targeting AL Amyloidosis and select immune-mediated diseases. The company operates through its wholly-owned Australian subsidiary and its cell therapy division, Nexcella, which merged into the company in 2024. Its lead product candidate, NXC-201, is a CAR-T cell therapy currently in Phase 1/2 clinical trials (NEXICART-2) for relapsed/refractory AL Amyloidosis. The company has received FDA Breakthrough Therapy Designation for NXC-201 and is progressing toward a Biologics License Application submission. Immix Biopharma has reported positive clinical data including a 70% complete response rate and a favorable safety profile. The company finances its operations primarily through equity financings and grants, with significant cash reserves as of late 2025. It faces typical risks of early-stage biotech firms including regulatory, clinical, and financing uncertainties.

Gesher Acquisition Corp. II is a special purpose acquisition company (SPAC) incorporated in August 2024 in the Cayman Islands. Its business model is to identify and complete a Business Combination with one or more target companies, primarily focusing on Israeli companies with international business in Asia, Europe, or North America. The company completed its IPO in March 2025, raising gross proceeds of approximately $144 million, which are held in a Trust Account to be used for the Business Combination. The company has no operating revenues and has not yet selected a target. Its management team has prior SPAC experience and focuses on sectors including mobility, electric vehicles, robotics, agricultural technologies, and financial technology. The company must complete its Business Combination by December 24, 2026, or liquidate and return funds to shareholders. It may raise additional capital through equity or debt to complete the transaction if necessary.

K&F Growth Acquisition Corp. II is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in July 2024. It was formed to identify and complete a Business Combination with one or more target companies in any industry. The company completed its IPO in February 2025, raising gross proceeds of approximately $287.5 million, with additional private placement proceeds of $9.2 million. The net proceeds were placed in a Trust Account to be used for the Business Combination. The company has not yet identified or entered into a definitive agreement with a target business and has no operating revenues. Its management team, led by Co-CEOs Edward King and Daniel Fetters, has prior experience completing a SPAC Business Combination. The company targets businesses with equity valuations greater than $1 billion, focusing on highly defensible business models with sustainable competitive advantages and strong secular growth. It maintains strong liquidity and reported net income for the fiscal year ended December 31, 2025. The company must complete its Business Combination by November 6, 2026, or liquidate and return funds to shareholders.

Enveric Biosciences, Inc. is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics aimed at addressing unmet needs in psychiatric and neurological disorders. The company’s lead drug candidate, EB-003, is a novel derivative of N,N-Dimethyltryptamine (DMT) designed to selectively engage serotonin receptors 5-HT 2A and 5-HT 1B to potentially provide fast-acting and durable antidepressant and anxiolytic effects without inducing hallucinations. EB-003 is currently in preclinical development, having completed short-term dose-range finding toxicology studies and advancing into IND-enabling safety pharmacology and longer-term toxicology studies. Enveric also pursues development of additional non-hallucinogenic molecules in its EVM401 Series targeting addiction and neuropsychiatric disorders. The company acquired MagicMed Industries in 2021, gaining access to the Psybrary™ proprietary library of psychedelic-inspired compounds, which includes a large portfolio of patent-protected chemical structures. Enveric holds rights to 19 active patent families related to psychedelic-inspired compounds and cannabinoid conjugates, some of which are licensed to third parties. The company has established a scientific advisory board comprising experts in psychiatry and psychopharmacology to guide its clinical development programs. As of December 31, 2025, Enveric had no approved products, reported a net loss of $8.77 million, and held $2.84 million in cash and equivalents with a current ratio of 5.38. The company has significant liquidity needs and may require additional funding to continue its operations and advance clinical trials.

SKYX Platforms Corp. is a Florida-incorporated company specializing in advanced-safe-smart platform technologies for electrical products such as light fixtures and ceiling fans. Its technology enables quick, safe plug-and-play installation without handling hazardous wiring. The company has evolved its product offerings to include smart features controlled via mobile applications, enhancing home safety and convenience. SKYX also markets third-party home lighting and furnishings. The company operates primarily in the United States with additional presence in China. It holds multiple patents and has engaged in strategic partnerships to expand its market reach. SKYX has a history of operating losses but has raised capital through equity offerings and convertible notes to support operations and growth initiatives [S1].

Fusemachines Inc. is an enterprise AI solutions provider offering a suite of AI products and services designed to help organizations integrate AI into their operations. Its core offerings include AI Studio, a platform for building and managing AI applications; AI Engines, specialized AI software targeting industry-specific challenges; and AI Agents, intelligent systems automating complex workflows. The company complements its products with services such as customization, model tuning, deployment, and bespoke AI solution development. Fusemachines also operates AI training programs to address the global shortage of skilled AI professionals. The company completed a business combination in 2025, becoming publicly traded. Its client base spans diverse industries including consumer brands, healthcare, media, technology, and government. Fusemachines holds intellectual property assets including patent applications and employs various IP protection strategies. The company reported $7.7 million in revenue and a net loss of $928,000 for the fiscal year ended December 31, 2025, with liquidity ratios indicating constrained short-term financial flexibility. It faces competition from internal corporate IT teams, commercial AI software providers, open-source platforms, cloud providers, and system integrators. Sales cycles are lengthy and resource-intensive, with customer concentration risk present. The company emphasizes human capital management, compliance, and intellectual property protection as key operational pillars.

Utah Medical Products, Inc. (UTMD) produces and markets a broad range of medical devices primarily used in critical care hospital settings such as neonatal intensive care units, labor and delivery departments, and women's health centers, as well as outpatient clinics and physician offices. The company emphasizes device safety, improved patient outcomes, and cost-effectiveness. UTMD's business model involves direct sales to clinical end-users and stocking distributors in the U.S., and direct sales plus independent distributors internationally, covering countries including Canada, UK, France, Ireland, Australia, and New Zealand. The company also manufactures components and finished devices on a subcontract basis for other medical device companies (OEM sales). UTMD has expanded through acquisitions and maintains manufacturing and distribution facilities in the U.S., Ireland, UK, Australia, Canada, and New Zealand. The company invests in product development focused on device improvements, new product introductions, and acquisitions or licensing of technology. UTMD holds multiple patents and trademarks, with trademarks providing significant brand recognition. The company faces competition from multiple competitors for each device type, competing primarily on clinical benefits and device reliability. UTMD's marketing strategy includes direct sales representatives, consultants, and manufacturer representatives focused on clinical applications and customer training. The company is exposed to risks from trade disruptions, tariffs, foreign currency fluctuations, and restricted access to clinicians in the U.S. market [S1].

DICK'S Sporting Goods, Inc. is a leading sporting goods retailer operating multiple store formats and an omni-channel platform. The company offers a broad assortment of products including exclusive vertical brand merchandise, which accounts for about 13% of sales in its DICK'S Business segment. It has expanded its retail experience through new store concepts featuring interactive and experiential elements. The company sources products from approximately 1500 vendors, with Nike as its largest supplier. It operates a global distribution and fulfillment network to support its stores and eCommerce operations. The company is actively integrating the Foot Locker Business as a standalone segment, aiming to leverage operational synergies. Its business is sensitive to macroeconomic factors affecting consumer discretionary spending and faces competitive pressures across retail channels. The company manages risks related to supply chain, inventory, regulatory compliance, and technological innovation.

Air Industries Group is a publicly traded company listed on the NYSE American exchange under the ticker AIRI. The company reported approximately $47.9 million in revenue for the full year 2025 and a net loss of $1.305 million. Its liquidity position as of the end of 2025 shows a current ratio of 1.24, indicating moderate short-term financial stability. The company has been involved in legal proceedings related to a sublease agreement, which it is contesting and does not currently expect to materially impact its financial condition. In February 2026, Air Industries Group entered into a merger agreement with Tenax Aerospace Acquisition, LLC, which involves issuing shares and creating a subsidiary. Recent quarterly financial results have shown losses but revenue exceeding estimates, and the company’s stock has experienced notable price fluctuations relative to the broader market.

Spartacus Acquisition Corp. II is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in November 2025. Its business model is to identify, acquire, and merge with one or more target businesses in any industry, thereby taking the combined entity public. The company completed its IPO in February 2026, raising $230 million, which is held in a trust account to fund the initial business combination. The management team has extensive experience in technology, media, and telecommunications sectors and aims to leverage their expertise and network to source and execute a business combination. The company has no operating revenues or selected target as of the latest filing and must complete the business combination within 24 months of the IPO or liquidate. The company’s structure offers target businesses an alternative to traditional IPOs, potentially providing a faster and more cost-effective path to public markets. The company faces competition from other SPACs and investment groups in sourcing suitable targets.

Daedalus Special Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in August 2025 in the Cayman Islands. It was formed to effect a merger or similar business combination with one or more businesses, with an initial focus on the consumer artificial intelligence (AI) sector. The company completed its IPO in December 2025, issuing 25 million units at $10 each, raising gross proceeds of $250 million, plus a private placement of 685,000 units raising $6.85 million. Proceeds are held in a trust account until an initial business combination is completed or the company liquidates. The management team includes seasoned professionals with experience in AI, mobile applications, gaming, financial technology, and capital markets. The company’s strategy is to acquire and scale a leading consumer AI company with a profitable subscription-driven model, leveraging operational expertise and pursuing market consolidation through acquisitions. The company has not yet selected a business combination target and has not initiated substantive discussions with any target. Financial snapshot as of December 31, 2025, shows current assets of $1.14 million, current liabilities of $0.2 million, a current ratio of 5.8, and net income of $370,459. The company currently has three officers and no full-time employees prior to a business combination.

SIM Acquisition Corp. I is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. The company has no operating history or revenues and is focused on identifying and completing an initial business combination with a target company. It is not limited to any particular industry or sector for its business combination. The company’s financial position as of December 31, 2025, shows limited current assets and liabilities, with a current ratio below 1. The company has disclosed substantial risks related to its ability to complete a business combination within the required timeframe, including competition for targets, regulatory challenges, and potential dilution from additional share issuances or debt. The company’s public shareholders have limited voting rights on the business combination, and founder shares may influence the outcome. The company has entered into administrative agreements and issued a promissory note to its sponsor for working capital. It is listed on Nasdaq under the ticker SIMA and is classified as an emerging growth company.

Knightscope, Inc. designs, manufactures, and leases Autonomous Security Robots (ASRs) and sells Electronic Control Devices (ECDs) alongside installation, maintenance, and upgrade services. The company’s business model includes recurring revenue from ASR leases and maintenance contracts, as well as product sales. Revenue recognition follows lease accounting for ASRs and point-in-time or over-time recognition for ECD sales and services. The company’s revenue for 2025 was $11.3 million, with service revenue comprising 70% and product revenue 30%. Despite revenue growth, Knightscope reported a gross loss and net loss for the year, reflecting high costs and investments in research and development. The company maintains liquidity with cash and equivalents of $20.6 million and a strong current ratio but continues to operate at a loss and requires additional financing to sustain operations. Supply chain challenges and customer concentration are notable operational factors. The company’s backlog stood at approximately $3.1 million as of March 2026 [S1].

Tenon Medical, Inc. develops and commercializes medical devices for the treatment of sacroiliac (SI) joint disorders, a significant cause of chronic lower back pain. The company offers two main systems: The Catamaran SI Joint Fusion System, a less invasive, single titanium implant approach cleared by the FDA in 2018 and commercially launched nationally in 2022, and the SImmetry + System, acquired in 2025, which uses a minimally invasive lateral access technique with 3D printed titanium implants. Tenon targets a U.S. market estimated at 270,000 annual SI Joint surgical procedures, currently underserved with 5-7% penetration. The company distributes products primarily through independent sales representatives to approximately 12,000 physicians specializing in spine and pelvic surgeries. Tenon emphasizes clinical outcomes such as pain reduction, patient satisfaction, and radiographic confirmation of fusion, supported by prospective clinical studies. The company faces supply chain risks due to reliance on a limited number of contract manufacturers without long-term agreements. Financially, Tenon reported $3.94 million in revenue and a net loss of $12.56 million for fiscal 2025, with liquidity ratios indicating moderate short-term financial health. The company recently raised approximately $4.3 million through convertible promissory notes and is addressing Nasdaq listing compliance due to its stock price falling below $1.00 per share.

Crown Reserve Acquisition Corp. I is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in April 2025. Its business model is to raise capital through an IPO and private placement to fund a future Business Combination with one or more target companies. The company completed its IPO in November 2025, issuing 17.25 million units and raising $172.5 million, which was placed in a Trust Account invested in short-term U.S. government securities. The company has no operations or employees and focuses on identifying a suitable acquisition target within a defined Combination Period of 12 months, extendable to 15 months. Management brings broad experience in technology, financial services, healthcare technology, and consumer sectors, with expertise in mergers and capital markets. The company’s securities trade on Nasdaq under multiple symbols representing shares, warrants, rights, and units. The company’s financial position as of December 31, 2025, shows net income of approximately $1.13 million and limited liquidity outside the Trust Account. The company faces typical SPAC risks including execution risk, competition for targets, and potential dilution.

Launchpad Cadenza Acquisition Corp I is a special purpose acquisition company (SPAC) incorporated in June 2025 in the Cayman Islands. Its business purpose is to identify and complete a Business Combination with one or more companies, focusing on technology and software infrastructure businesses within blockchain, fintech, and digital assets ecosystems. The company completed its IPO in December 2025, issuing 23 million Units at $10 each, raising $230 million placed in a Trust Account. The Management Team and Advisors have extensive experience in fintech and SPAC transactions. The company has not yet selected a Business Combination target and has no operating revenues. It aims to complete a Business Combination by December 19, 2027, or liquidate and return funds to shareholders if unsuccessful. The company maintains strong liquidity with a current ratio of 12.58 as of the end of 2025 and reported a small net income for the fiscal year 2025.

Abony Acquisition Corp. I is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in November 2025. It was formed to identify and complete a merger or similar business combination with one or more target companies, focusing on businesses with enterprise values between $750 million and $1.5 billion in sectors such as defense technology, advanced computing, software, and media. The company completed its initial public offering in February 2026, raising gross proceeds of $230 million, which are held in a trust account to fund the business combination. The company has not commenced operations or generated revenues and incurs costs related to administration and preparation for the business combination. The management team brings extensive experience in scaling public companies, capital markets, and SPAC transactions. The company has a 24-month window to complete its initial business combination, with possible extensions subject to shareholder approval.

Functional Brands Inc. operates in the nutraceutical supplement industry, manufacturing and distributing dietary supplements across multiple health categories. Its principal business is conducted through the Kirkman division, which offers over 150 products including vitamins, probiotics, enzymes, and specialty supplements. The company markets products through pharmacies, wholesalers, international distributors, and direct-to-consumer channels, including online platforms. It has a significant customer relationship with iHerb, accounting for a substantial portion of revenue. The company has expanded its offerings with the launch of the P2i by Kirkman certified prenatal vitamin and the Tru2u.health digital health platform, which integrates telehealth services and wellness supplements. Functional Brands completed a Nasdaq direct listing in November 2025 and has engaged in capital restructuring involving convertible preferred stock. The company maintains manufacturing in an FDA registered, cGMP certified facility in Oregon and emphasizes product purity and quality standards.

1606 Corp. was incorporated in Nevada in 2021 as a spin-off from Singlepoint Inc. Initially engaged in selling tobacco- and nicotine-free hemp cigarettes, the company discontinued that business and pivoted in 2023 to AI chatbot technology focused on the CBD industry. The company developed proprietary AI chatbots, including 'chatCBDW' for CBD retailers and 'IRChat' for public companies, delivered via a monthly licensing fee model. 1606 Corp. leverages independent sales organizations to distribute its chatbot solutions. The company has a team with extensive AI and technology experience and owns intellectual property related to its chatbot technology. In late 2025 and early 2026, 1606 Corp. began acquiring power generation and data center infrastructure assets in Texas to support AI and data center operations, including a 55 MW power generation facility and a 50,000 square foot climate-controlled warehouse on 132 acres. The company has not yet secured full financing for these acquisitions and has no prior experience operating power generation or data center facilities. The company reported no revenue and a net loss for the fiscal year ended 2025, with limited liquidity and significant current liabilities. The CEO is the sole full-time employee, supported by contractors and consultants. The company is headquartered in Phoenix, Arizona.

SPACSphere Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands, designed to raise capital through an IPO to acquire or merge with one or more operating businesses. The company completed its IPO in February 2026, issuing 17.25 million units and raising $172.5 million in gross proceeds, which are held in a trust account invested in low-risk U.S. government securities. The company has not yet selected any acquisition targets and is not restricted to any industry or geography. Its management team brings extensive experience in business growth, investment, and acquisitions. The company’s acquisition criteria emphasize competitive positioning, management quality, growth potential, and risk-adjusted returns. The company has a single reportable segment and has incurred net losses related to administrative expenses since inception.

PAVmed Inc. operates as a diversified life sciences company with a focus on medical devices, diagnostics, and digital health through independently financed subsidiaries. Its primary subsidiaries are Lucid Diagnostics, which commercializes the EsoGuard Esophageal DNA Test and EsoCheck device for early detection of esophageal precancer and cancer, and Veris Health, which provides a digital cancer care platform aimed at improving personalized cancer care and monitoring. PAVmed also develops medical devices such as the PortIO implantable intraosseous vascular access device and licensed endoscopic imaging technology. The company pursues commercialization through multiple channels, including physician offices, test centers, telemedicine, and direct contracting with employers and health systems. It actively seeks reimbursement coverage and has secured contracts such as the U.S. Department of Veterans Affairs agreement for EsoGuard. Veris Health operates on a SaaS recurring revenue model with strategic partnerships at academic oncology centers. PAVmed's regulatory strategy includes FDA Breakthrough Device Designation and CE Mark certifications. The company faces competition from established and emerging players in diagnostics and digital health, and it manages liquidity constraints with ongoing capital raising efforts.

Soulpower Acquisition Corp. is a Cayman Islands exempted company operating as a Special Purpose Acquisition Company (SPAC) listed on the New York Stock Exchange under the ticker SOUL. The company has entered into a definitive business combination agreement with SWB LLC, a Cayman Islands limited liability company, to form a new public company. This transaction aims to create a new economy financial services conglomerate, including a stablecoin-denominated AI bank under the brand SOUL WORLD BANK™. The combined entity plans to operate as a licensed international financial institution with diverse financial lines and tokenized asset offerings. The business combination agreement was signed on November 24, 2025, with a pre-money valuation of approximately $8.1 billion based on contributed assets. The company has filed a confidential draft registration statement on Form S-4 with the SEC as part of the regulatory process. Financially, as of December 31, 2025, Soulpower reported current assets of approximately $1.5 million and current liabilities of approximately $1.68 million, resulting in a current ratio below 1. The company reported net income of about $6 million for the fiscal year ended December 31, 2025, and basic and diluted earnings per share of -$0.02 for the first quarter of 2025. The business combination remains subject to shareholder approval and regulatory clearances. The company is classified as an emerging growth company and has issued unsecured promissory notes to support working capital needs.

Presidio Property Trust, Inc. is a publicly traded, internally-managed REIT incorporated in Maryland, owning a portfolio of commercial real estate and model home properties across multiple U.S. states. The commercial portfolio includes office, industrial, and retail properties leased to a diversified tenant base, while the model home portfolio consists of single-family model homes leased back to homebuilders under triple-net leases. The company focuses on acquiring stabilized or near-stabilized properties in regionally dominant markets with favorable economic and demographic trends. It operates several affiliated limited partnerships for its model home business and provides management services to these entities. The company pursues value creation through selective acquisitions, dispositions, and active portfolio management, including share repurchase programs and capital raising initiatives.

BioXcel Therapeutics, Inc. operates as a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines primarily in neuroscience and immuno-oncology. The company’s proprietary AI platform, EvolverAI, identifies new therapeutic indications by analyzing existing drugs and clinical data to reduce development costs and timelines. Its lead neuroscience product, BXCL501, marketed as IGALMI®, is FDA-approved for acute treatment of agitation in schizophrenia and bipolar I or II disorder, with ongoing clinical development for at-home use. The immuno-oncology pipeline includes BXCL701, an investigational oral innate immune activator targeting aggressive cancers. BioXcel relies on third-party manufacturers and clinical trial operators. The company faces extensive regulatory requirements and market acceptance challenges. As of December 31, 2025, BioXcel reported a net loss and negative earnings per share, with liquidity ratios below 1, indicating current liabilities exceed current assets.

Alussa Energy Acquisition Corp. II is a Cayman Islands exempted blank check company incorporated in August 2024. Its purpose is to identify and complete a business combination with one or more companies primarily in the energy and power infrastructure sectors, with a focus on renewable energy transition. The company completed its IPO in November 2025, raising gross proceeds of $287.5 million, which are held in a Trust Account to fund the initial Business Combination. The company has not yet identified a target and has no operating revenues. The management team has extensive experience in energy, capital markets, and SPAC transactions, including prior successful business combinations. The company aims to acquire businesses with enterprise values between $1.0 billion and $1.5 billion but may consider other sizes. It must complete the Business Combination by November 14, 2027, or liquidate and return funds to shareholders. The company reported a net loss of $7.4 million for 2025, driven by advisory fees and administrative costs, partially offset by interest income from the Trust Account. As of December 31, 2025, it had a current ratio of 4.62, indicating strong liquidity.

Manhattan Bridge Capital, Inc. is a specialized real estate finance company that originates, services, and manages a portfolio of short-term, secured first mortgage loans primarily in the New York metropolitan area and Florida. The loans are typically for one year, secured by residential or commercial real estate, and personally guaranteed by borrower principals. The company operates as a REIT, distributing at least 90% of taxable income to shareholders. It maintains credit facilities with Webster Bank, Flushing Bank, and Valley National Bank to support its lending activities. The company emphasizes disciplined underwriting, flexible loan structuring, and quick execution to serve small real estate developers and investors. Its loan portfolio is concentrated but diversified across residential, commercial, and mixed-use properties. The company has a history of capital preservation with minimal foreclosures and focuses on generating attractive risk-adjusted returns primarily through dividends.

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel cancer immunotherapies, including oncolytic virus platforms. The company manages its operations as a single segment encompassing research, development, and commercialization activities. Its product candidates are in various stages of preclinical and clinical development, including CLD-101 for recurrent glioma, CLD-201 for solid tumors, and CLD-401 with clinical trials initiated in Australia. Calidi has not yet generated commercial revenues and depends on capital raises to fund its operations. The company operates subsidiaries in Germany and Australia to support clinical trial activities. It is classified as an emerging growth company and smaller reporting company, which affords certain regulatory reporting exemptions. The company faces typical early-stage biotech risks including long development cycles, regulatory approvals, and capital requirements [S1][N1][N8].

GD Culture Group Ltd is a company focused on live-streaming e-commerce primarily on the TikTok platform. It discontinued its online livestreaming gaming business in early 2025. The company has pursued growth through strategic acquisitions, including Pallas Capital Holding, and capital raising activities such as private placements and a significant common stock purchase agreement aimed at enhancing its crypto asset treasury strategy. GD Culture holds substantial Bitcoin assets as part of its treasury. The company relies heavily on TikTok for its business operations, including inventory management and live streaming channels. It faces competition in the emerging TikTok live-streaming e-commerce market, which is currently less intense than in Asian markets but expected to become more competitive. GD Culture has not established a history of recurring operating revenues and depends on capital raises and future revenue generation to sustain operations. The company is subject to regulatory risks in the PRC, cybersecurity threats, and operational risks related to e-commerce fraud and employee conduct. It is a smaller reporting company with reduced disclosure requirements and has announced a share repurchase program to return value to shareholders [S1][S2][N1][N2][N3][N4][N5][N6][N8].

Vale S.A. is a multinational mining company engaged in the extraction, processing, and sale of iron ore, pellets, nickel, copper, and other base metals. The company operates globally with a significant customer base in Asia, particularly China, as well as in the Americas and Europe. Its business segments include Iron Ore Solutions and Vale Base Metals, each contributing to revenue and profitability through production volumes and commodity prices. Vale's operations include mining, logistics, and energy production related to its core mining activities. The company invests in sustaining and growth capital expenditures and manages remediation obligations related to past dam failures. Vale maintains a diversified shareholder base and complies with financial covenants on its debt. It also implements comprehensive executive compensation programs aligned with performance and shareholder interests.